Heading Back to the Trough (Levels of Biologics in IBD)

被引：7
|
作者：
Hanauer, Stephen B. [1 ,2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Med, Digest Hlth Clin, Chicago, IL USA
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2015年 / 13卷 / 03期
关键词：
RHEUMATOID-ARTHRITIS PATIENTS; CROHNS-DISEASE; MAINTENANCE THERAPY; CLINICAL REMISSION; EPISODIC TREATMENT; INFLIXIMAB; ADALIMUMAB; ANTIBODY; DRUG; IMMUNOGENICITY;
D O I：
10.1016/j.cgh.2014.10.007
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：548 / 551
页数：4
相关论文
共 50 条
  • [41] In IBD Outpatients Knowledge of Fecal Calprotectin and Infliximab Trough Levels Significantly Alters Clinical Decision Making
    Huang, Vivian
    Kroeker, Karen I.
    Wang, Haili
    Prosser, Connie
    Carol, Shalapay
    Dhami, Neil
    Fedorak, Darryl K.
    Fedorak, Richard N.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S241 - S242
  • [42] Serum vedolizumab trough levels are associated with remission rate but not with extra-intestinal manifestations in IBD patients
    Tzadok, R.
    Fliss-Isakov, N.
    Cohen, N. Aviv
    Ron, Y.
    Maharshak, N.
    Hirsch, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S441 - S442
  • [43] Influence of Combination Therapy with Immune Modulators on Anti-TNF Trough Levels and Antibodies in Patients with IBD
    van Schaik, Tamara
    Maljaars, Jeroen P. W.
    Roopram, Rajiv K.
    Verwey, Marthe H.
    Ipenburg, Nienke
    Hardwick, James C. H.
    Veenendaal, Roeland A.
    van der Meulen-de Jong, Andrea E.
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : 2292 - 2298
  • [44] The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
    Lobaton, T.
    Canete, F.
    Teniente, A.
    Cabre, E.
    Manosa, M.
    Martinez, E.
    Domenech, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S265 - S265
  • [45] Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy
    Ungaro, Ryan
    Jossen, Jacqueline
    Phan, Becky
    Chefitz, Ezra
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S7 - S7
  • [46] HIGH INFLIXIMAB TROUGH LEVELS HAVE NO IMPACT ON FATIGUE IN IBD PATIENTS IN ENDOSCOPIC REMISSION: A PROSPECTIVE COHORT STUDY
    Borren, Nienke Z.
    Frinack, Jody L.
    Olson, Ryan N.
    Van der Woude, Christien Janneke
    Willrich, Maria Alice V.
    Ananthakrishnan, Ashwin
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S436 - S437
  • [47] Use of Immunomodulators or Biologics and Risk of Pneumonia Among IBD Patients
    Barffour, Maxwell
    Gandhi, Mustafa
    Reznicek, Emily
    Chela, Harleen
    Frimpong, Kwame
    Luton, Kevin
    Karanja, Elizabeth
    Bosak, Emily
    Bechtold, Matthew
    Ghouri, Yezaz
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S904 - S905
  • [48] AN EVALUATION OF THE IMPACT OF A VIRTUAL BIOLOGICS CLINIC ON SURROGATE BIOMARKERS IN IBD
    Merchant, Lynne
    Davidson, Katherine
    Souter, Caroline
    Morecroft, Charles
    Arnott, Ian
    [J]. GUT, 2021, 70 : A232 - A232
  • [49] The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
    Mak, Joyce W. Y.
    Sung, Joseph J. Y.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (08) : 1269 - 1270
  • [50] Clinical perspectives - Biologics in IBD: What's all the fuss?
    Steinhart, H
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 2001, 15 (12): : 799 - 804
12345